论文部分内容阅读
目的:探讨血清CA125、CA19-9、CEA、AFP联检在卵巢癌诊断中的应用价值。方法:选取2011年1月~2012年7月于该院进行诊治的38例卵巢癌患者为观察组,同期的38例卵巢良性肿瘤患者为对照组,后将两组患者的血清CA125、CA19-9、CEA及AFP水平与阳性率进行统计及比较。结果:观察组的血清CA125、CA19-9、CEA及AFP水平与阳性率均高于对照组,且4项联合检测阳性率明显高于单项检测,并且观察组不同分期患者存在明显的差异,P值均<0.05,均有统计学差异。结论:血清CA125、CA19-9、CEA、AFP联检在卵巢癌的诊断中的应用价值较高,对于分期的了解也有积极的临床意义。
Objective: To investigate the value of combined detection of serum CA125, CA19-9, CEA and AFP in the diagnosis of ovarian cancer. Methods: Thirty-eight patients with ovarian cancer diagnosed and treated in this hospital from January 2011 to July 2012 were selected as the observation group. 38 patients with benign ovarian tumors were selected as the control group. Serum levels of CA125, CA19- 9, CEA and AFP levels and positive rate statistics and comparison. Results: The serum levels of CA125, CA19-9, CEA and AFP in the observation group were higher than those in the control group, and the positive rates of the four combined tests were significantly higher than those of the single test group. There were significant differences in the observation group with different stages of P Values <0.05, all with statistical difference. Conclusion: The combination of serum CA125, CA19-9, CEA and AFP is of high value in the diagnosis of ovarian cancer, and has positive clinical significance for the understanding of staging.